login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
VAXXINITY INC-A (VAXX) Stock News
USA
-
Nasdaq
- NASDAQ:VAXX -
US92244V1044
-
Common Stock
0.1111
USD
-0.02 (-15.26%)
Last: 5/8/2024, 8:24:57 PM
0.1107
USD
0 (-0.36%)
After Hours:
5/8/2024, 8:24:57 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
VAXX Latest News, Press Relases and Analysis
All
Press Releases
a year ago - By: Vaxxinity, Inc.
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine
a year ago - By: Vaxxinity, Inc.
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine
2 years ago - By: Benzinga
- Mentions:
SPTS
SGBX
MRIN
SPT
...
Dow Jumps Over 400 Points; US Adds 175,000 Jobs In April
2 years ago - By: InvestorPlace
- Mentions:
CFBK
SPT
HSDT
Why Is CF Bankshares (CFBK) Stock Down 19% Today?
2 years ago - By: InvestorPlace
- Mentions:
SPT
HSDT
Why Is Sprout Social (SPT) Stock Down 32% Today?
2 years ago - By: InvestorPlace
- Mentions:
HSDT
Why Is Vaxxinity (VAXX) Stock Up 39% Today?
2 years ago - By: Benzinga
Why Vaxxinity (VAXX) Shares Are Volatile Today
2 years ago - By: InvestorPlace
- Mentions:
OLB
MLEC
Why Is Vaxxinity (VAXX) Stock Down 58% Today?
2 years ago - By: InvestorPlace
- Mentions:
HSDT
LOCO
ARDX
OSPN
...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
2 years ago - By: Vaxxinity, Inc.
Vaxxinity Issues Shareholder Letter
2 years ago - By: BusinessInsider
VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023
2 years ago - By: InvestorPlace
VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023
2 years ago - By: InvestorPlace
- Mentions:
NKE
TSLA
HEPA
Nike Layoffs 2024: What to Know About the Latest Nike Job Cuts
2 years ago - By: InvestorPlace
- Mentions:
HEPA
OLB
MLEC
Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?
2 years ago - By: InvestorPlace
- Mentions:
MLEC
OLB
CSLR
SPCB
...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
2 years ago - By: Vaxxinity, Inc.
Vaxxinity Issues Shareholder Letter
2 years ago - By: Vaxxinity, Inc.
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
2 years ago - By: Vaxxinity, Inc.
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
2 years ago - By: Vaxxinity, Inc.
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
2 years ago - By: Vaxxinity, Inc.
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
2 years ago - By: Vaxxinity, Inc.
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
2 years ago - By: Vaxxinity, Inc.
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
2 years ago - By: Vaxxinity, Inc.
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
2 years ago - By: Vaxxinity, Inc.
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
Please enable JavaScript to continue using this application.